mRNA vaccine in cancer therapy: Current advance and future outlook

Author:

Li Youhuai1,Wang Mina23,Peng Xueqiang4,Yang Yingying5,Chen Qishuang2,Liu Jiaxing4,She Qing1,Tan Jichao1,Lou Chuyuan6,Liao Zehuan78ORCID,Li Xuexin9ORCID

Affiliation:

1. Department of Breast Surgery Baoji Municipal Central Hospital Weibin District Baoji Shaanxi China

2. Graduate School Beijing University of Chinese Medicine Beijing China

3. Department of Acupuncture and Moxibustion Beijing Hospital of Traditional Chinese Medicine Capital Medical University Beijing Key Laboratory of Acupuncture Neuromodulation Beijing China

4. Department of General Surgery The Fourth Affiliated Hospital China Medical University Shenyang China

5. Clinical Research Center Shanghai Key Laboratory of Maternal Fetal Medicine Shanghai Institute of Maternal‐Fetal Medicine and Gynecologic Oncology Shanghai First Maternity and Infant Hospital School of Medicine Tongji University Shanghai China

6. Department of Ophthalmology Xi'an People's Hospital (Xi'an Fourth Hospital) Xi'an Shaanxi China

7. School of Biological Sciences Nanyang Technological University Singapore Singapore

8. Department of Microbiology, Tumor and Cell Biology (MTC) Karolinska Institutet Sweden

9. Department of Medical Biochemistry and Biophysics (MBB) Karolinska Institutet Biomedicum Stockholm Sweden

Abstract

AbstractMessenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer. In the past 2 years, SARS‐CoV‐2 mRNA vaccines have contributed tremendously against SARS‐CoV2, which has prompted the arrival of the mRNA vaccine research boom, especially in the research of cancer vaccines. Compared with conventional cancer vaccines, mRNA vaccines have significant advantages, including efficient production of protective immune responses, relatively low side effects and lower cost of acquisition. In this review, we elaborated on the development of cancer vaccines and mRNA cancer vaccines, as well as the potential biological mechanisms of mRNA cancer vaccines and the latest progress in various tumour treatments, and discussed the challenges and future directions for the field.

Funder

China Postdoctoral Science Foundation

Natural Science Foundation of Liaoning Province

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Reference217 articles.

1. Cancer Immunotherapy

2. The Intriguing History of Cancer Immunotherapy

3. The effect of a bacterial vaccine on tumors and the immune response of ICR/Ha mice;Havas HF;J Biol Response Mod,1990

4. Neoadjuvant checkpoint blockade for cancer immunotherapy

Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3